Asset
Crinecerfont
Neurocrine Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04490915 | phase3 | active_not_recruiting | 2020-12-16 | 2023-07-19 | Neurocrine Biosciences | Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia |
| NCT04806451 | phase3 | active_not_recruiting | 2021-06-25 | 2023-03-10 | Neurocrine Biosciences | Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) |
| NCT07187375 | phase2 | active_not_recruiting | 2025-09-30 | 2029-09-06 | Neurocrine Switzerland GmbH | Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old |
| NCT07536269 | phase2 | not_yet_recruiting | 2026-04-01 | 2028-03-01 | Neurocrine Biosciences | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old |
| NCT04045145 | phase2 | completed | 2019-12-12 | 2021-07-02 | Neurocrine Biosciences | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 218808 | NDA | NEUROCRINE BIOSCIENCES INC |
| NDA 218820 | NDA | NEUROCRINE BIOSCIENCES INC |
Marketed products (4)
- CRENESSITY
- CRENESSITY
- CRENESSITY
- CRENESSITY